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Abstract: In this study, series of ring-substituted 2-styrylquinazolin-4(3H)-one and  
4-chloro-2-styrylquinazoline derivatives were prepared. The syntheses of the discussed 
compounds are presented. The compounds were analyzed by RP-HPLC to determine 
lipophilicity. They were tested for their inhibitory activity on photosynthetic electron 
transport (PET) in spinach (Spinacia oleracea L.) chloroplasts. Primary in vitro screening 
of the synthesized compounds was also performed against four mycobacterial strains and 
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against eight fungal strains. Several compounds showed biological activity comparable 
with or higher than that of the standard isoniazid. It was found that the electronic 
properties of the R substituent, and not the total lipophilicity of the compound, were 
decisive for the photosynthesis-inhibiting activity of tested compounds. 
Keywords: styrylquinazolinone and styrylquinazoline derivatives; lipophilicity; PET 
inhibition; spinach chloroplasts; in vitro antimycobacterial activity; in vitro antifungal 
activity; structure-activity relationships 
 
1. Introduction 
A quinoline moiety is present in many classes of biologically-active compounds. A number of them 
have been clinically used as antifungal, antibacterial and antiprotozoic drugs [1,2], as well as 
antituberculotic agents [3-5]. Some quinoline-based compounds have also shown antineoplastic, 
antiasthmatic and antiplatelet activity [6-11]. A series of compounds derived from 8-hydroxyquinoline 
and styrylquinoline derivatives were recently synthesized as potential HIV-1 integrase inhibitors  
[12-15]. Our previous study dealing with 8-hydroxyquinoline and styrylquinoline derivatives showed 
that they could also possess strong antifungal activity [16,17]. According to recently reported results, 
some new hydroxyquinoline derivatives also possess interesting herbicidal activities  
[16,18-20]. In addition, some of the investigated quinoline derivatives also showed antineoplastic 
activity [18,21]. 
Over 50% of commercially available herbicides act by reversibly binding to photosystem II (PS II), 
a membrane-protein complex in the thylakoid membranes which catalyses the oxidation of water and 
the reduction of plastoquinone [22] and thereby inhibit photosynthesis [23-25]. Some organic 
compounds, e.g. substituted benzanilides [26] or substituted anilides of 2,6-disubstituted  
pyridine-4-thiocarboxamides [27] or pyrazine-2-carboxylic acids [28,29] were found to interact with 
tyrosine radicals TyrZ and TyrD which are situated in D1 and D2 proteins on the donor side of PS II. 
Due to this interaction interruption of the photosynthetic electron transport occurred. 
Tuberculosis (TB) is a worldwide pandemic. About 1/3 of the world's population is infected with 
Mycobacterium tuberculosis, and almost two million people die every year as a result. A large number 
of infected people are carriers of the latent form, which creates a potentially dangerous future source 
of the illness. The HIV pandemic has also led to the rapid growth of the TB epidemic, and increased 
the likelihood of people dying of TB. Another factor contributing to the rise in TB infections, and 
consequently to the increased number of deaths, is the appearance of multiple drug-resistance (MDR), 
i.e., rise of multidrug-resistant TB (MDR-TB) [30,31]. 
The Mycobacterium genus is composed of the M. tuberculosis complex and other species known as 
nontuberculous mycobacteria (NTM, or MOTT – mycobacteria other than tuberculosis). In recent 
decades, the decrease in the prevalence of tuberculosis in developed countries has resulted in an 
increase in the proportion of diseases caused by NTM [32]. Among these species, the M. avium 
complex (MAC) has emerged as a major human pathogen, being a common cause of disseminated 
disease and death in patients with HIV/AIDS [33]. 
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Chronic pulmonary disease is the most common clinical manifestation among the diseases caused 
by NTM, and the most common pathogens are the species belonging to the MAC, followed by  
M. kansasii. The clinical characteristics of NTM-related pulmonary disease are, in many cases, 
extremely similar to those of tuberculosis. Other clinical manifestations are caused principally by  
M. fortuitum, M. smegmatis and M. abscessus due to peritoneal infection as a result of catheterization 
or postsurgical infections [34]. The above mentioned non-tuberculous strains are sometimes resistant 
to commonly used drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) and other 
antituberculous drugs [30]. Therefore, systematic development of new effective compounds is 
necessary. Similarly, there is also an urgent need for discovery of new drugs with novel modes of 
action for the treatment of systemic mycoses. This is due to the rapid growth of the 
immunocompromised patient population and development of resistance to current azole therapies, and 
the high toxicity of polyenes [35]. It should be stressed that hydroxyquinolines and their derivatives 
were introduced as antifungal or antimycobacterial agents in clinical practice and novel compounds of 
this type are still being investigated [3-5,36,37]. 
This is a follow-up paper to our previous articles [12-21] dealing with synthesis and biological 
activities of ring-substituted quinazolinone derivatives. In the context of our previously-described 
azanaphtalenes, new modifications of quinoline moiety that can trigger interesting biological activity 
were investigated. 
Primary in vitro screening of the synthesized compounds was performed against four mycobacterial 
strains and against eight fungal strains. The compounds were also tested for their photosynthesis-
inhibiting activity (the inhibition of photosynthetic electron transport) in spinach chloroplasts 
(Spinacia oleracea L.). Lipophilicity (log k) of the compounds was determined using RP-HPLC. 
Relationships among the structure and in vitro antimicrobial activities or/and inhibitory activity 
related to inhibition of photosynthetic electron transport (PET) in spinach chloroplasts of the new 
compounds are discussed. 
2. Results and Discussion 
2.1. Chemistry 
All the studied compounds were prepared according to Scheme 1. Microwave-assisted synthesis 
facilitated the preparation of quinazoline-related structures. 2-Methyl-4H-benzo[d][1,3]oxazin-4-one 
was synthesized from anthranilic acid and acetic anhydride. A further reaction with ammonia or 
hydroxylamine afforded 2-methylquinazolin-4(3H)-one (1) or 3-(2-hydroxyethyl)-2-methylquinazolin-
4(3H)-one (2). 2-Styrylquinazolin-4(3H)-ones 3a-k were obtained from appropriate aldehydes using 
neat microwave-assisted synthesis [38]. Further chlorination/dehydratation with POCl3 yielded  
4-chloro-2-styrylquinazoline derivatives 4a-e. Styrylquinazolines can exist as E- or Z-isomers 
according to the orientation of the ethylene linker. This can greatly affect their biological activity  
i.e., behaviour at the site of action and complexation mechanism(s). Thus we have studied the 
isomerism of all the obtained compounds with NMR techniques and crystallography, as formerly 
described for similar structures [39,40]. Fortunately this feature can be easily determined by 
examination of the coupling constants of both vinyl protons in the spectra. These are much higher in 
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the case of E-isomers (J > 16 Hz) compared to Z-isomers (J < 12 Hz) [39]. All styrylquinazolines were 
found to be pure E-isomers, which is in good agreement with previous results [13,17,18,39,40]. 
Scheme 1. Synthetic pathway and general formula of prepared quinazolinone derivatives:  
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Reagents and Conditions: a) Ac2O, MW; b) NH3aq, MW; c) NH2C2H4OH, MW; d) aldehyde, MW; 
e) POCl3. 
2.2. Lipophilicity 
Many low molecular weight drugs cross biological membranes through passive transport, which 
strongly depends on their lipophilicity. Lipophilicity is a property that has a major effect on 
absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) properties, as well as 
pharmacological activity. Lipophilicity has been studied and applied as an important drug property for 
decades [41]. 
This thermodynamic parameter describes the partitioning of a compound between aqueous and 
organic phases and is characterized by the partition (log P) coefficient [42,43]. With new 
computerized methods of log P calculation, the possibility of predicting hydrophobicity in large 
libraries of compounds came into being. Lipophilicity computing software can usually calculate log P 
and Clog P. The software calculates log P values as lipophilicity contributions/increments of 
individual atoms, fragments and the pairs of interacting fragments in the chemical structure, i.e., 
increments of carbon and hetero atoms, aromatic systems and functional groups. The software 
calculates lipophilicity contributions according to different internal databases/libraries, so the 
calculated lipophilicity values are dependent on the software used, and the values for individual 
compounds may be different. This fact, as well as various ionic/zwitterionic forms and intramolecular 
interactions, may cause differences between calculated and experimentally determined lipophilicities. 
Classical methods for determination of these partition constants are time consuming and not always 
adequately reliable. It was recognised some time ago that the retention of a compound in reversed-
phase liquid chromatography is governed by its lipophilicity, and thus shows correlation with the 
octanol–water partition coefficient [44]. Reversed phase high performance liquid chromatography  
(RP-HPLC) provides an excellent platform for computer controlled automated measurements with 
computerised data acquisition for a large number of investigated compounds. Other advantages in the 
use of HPLC retention data for lipophilicity determination are the absence of need for concentration 
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determination and method validation, simultaneous separation of small impurities from the main 
component, sufficiency of small amounts of material for measurements and possibility of their full 
automation. Therefore the investigation of the true potential of this method is of great importance [45]. 
The effect of stationary and mobile phase selection has been published by van der Waterbeemd et 
al. [43] and more recently by Claessens et al. [46]. RP-HPLC methods have become popular and 
widely used for lipophilicity measurement [47]. A general procedure is the measurement of the 
directly accessible retention time under isocratic conditions with varying amounts of methanol as an 
organic modifier in the mobile phase using end-capped non-polar C18 stationary RP columns and 
calculating the logarithm of capacity factors (log k). Log k is the logarithm of capacity factors in 
chromatographic approaches, which is related to the partitioning of a compound between a mobile and 
a (pseudo-)stationary phase. Log k is used as the lipophilicity index converted to log P scale [43,45-49]. 
Some groups have used a C18 chromatographic column with methanol-water mobile phases to 
obtain log kw, i.e., the retention factor extrapolated to 0% organic modifier, as an alternative to log P 
[50]. The log kw is obtained by performing several measurements with various ratios of water/organic 
solvent. Nevertheless determination of log kw has some disadvantages in that it is time consuming due 
to the various measurements that need to be undertaken before calculation of log kw [44]. The main 
reason for the measurement is that it is more convenient to perform a systematic study of log k of 
various heteroaromatic compounds using mobile phases containing around 50% methanol due to 
various intramolecular interactions between heteroatoms and substituents [51-53]. Therefore this study 
was performed using methanol/water (55:45) as the mobile phase. The conditions (non-buffered 
mobile phase) were chosen with respect to conditions of biological evaluations, which are performed 
mostly under neutral conditions (pH ~ 7). The lipophilicity data can be strongly influenced by 
intramolecular interactions under the applied chromatographic conditions which were investigated in 
the paper [54,55]. 
Lipophilicities (log P/Clog P) of all eighteen compounds 1-4e were calculated using two 
commercially available programs (ChemDraw Ultra and ACD/LogP) and also measured by means of 
the RP-HPLC determination of capacity factors k with subsequent calculation of log k. The procedure 
was performed under isocratic conditions. Neither programme succeeded in resolving the differing 
lipophilicity values of individual positional isomers inasmuch as the same log P/Clog P values were 
calculated for 3b-d, 3g-i and 4b-d. The results are shown in Table 1 and illustrated in Figure 1. 
The results obtained with respect to all compounds show that the experimentally-determined 
lipophilicities (log k values) of all compounds are lower than those indicated by the calculated  
log P/Clog P, as shown in Figure 1, indicating that experimentally-determined log k values correlate 
relatively poorly with the calculated log P/Clog P. These facts are caused by both the above 
mentioned limitation of the software programmes used and also possibly to intramolecular interactions 
between heterocyclic nitrogens and substituents [19,54-59]. As expected, compound 3i showed the 
highest lipophilicity, while compound 1 exhibited the lowest. Series 4a-e showed lower lipophilicity 
(log k) than series 3a-e, contrary to all calculated log P/Clog P data. The higher lipophilicity of 3a-e 
compared with 4a-e is caused by intramolecular interactions between N(3) and carbonyl oxygen in the 
position 4. Similar interactions were described recently [19,55-59]. This hypothesis can be supported 
by the fact that log k of 1 was lower than 2, although this is contrary to calculated log P/Clog P. When 
the lipophilicity of both compounds was calculated with intramolecular interactions between  
Molecules 2009, 14                            
 
 
4251
N(3)-H···O=C(4), the lipophilicity increased (Clog P (1): 1.343 and Clog P (2): 2.2306). Similar facts 
may be observed at 3a-e and 4a-e, therefore the experimental log k data of 4a-e were slightly lower 
than those log k of 3a-e. 
Table 1. Comparison of the calculated lipophilicities (log P/Clog P) with the determined 
log k values, electronic Hammett's parameters (σ) and bulk parameters MR (volume of 
substituents) [60]. 
Comp. R log k 
log P/Clog P 
ChemOffice 
log P 
ACD/LogP 
σ [60] MR [60]
1 
N
NH
O
0.1170 0.98 / 0.804 -0.36 ± 0.59 – – 
2 
N
N
O
OH
 
0.7047 0.69 / 0.6149 -1.23 ± 0.69 – – 
N
NH
O
R
3a H 1.1148 3.21 / 2.997 2.37 ± 0.61 0.0 0.0 
3b 2-OCH3 1.1509 3.09 / 2.916 2.35 ± 0.62 -0.390 [61] 6.5 
3c 3-OCH3 1.1837 3.09 / 2.916 2.35 ± 0.62 0.115 6.5 
3d 4-OCH3 1.1351 3.09 / 2.916 2.32 ± 0.62 -0.268 6.5 
3e 2,4-OCH3 1.1982 2.96 / 3.005 2.20 ± 0.62 -0.658 13.0 
3f 3-Cl 1.5059 3.77 / 3.710 2.96 ± 0.61 0.373 4.8 
3g 2-Br 1.4830 4.04 / 3.860 3.14 ± 0.64 – 7.6 
3h 3-Br 1.5904 4.04 / 3.860 3.14 ± 0.64 0.391 7.6 
3i 4-Br 1.5927 4.04 / 3.860 3.14 ± 0.64 0.232 7.6 
3j 4-CHO 0.8005 2.96 / 2.350 1.79 ± 0.63 1.030 5.3 
3k 2,3,4-OH 0.5510 2.05 / 1.066 1.84 ± 0.63 – 4.5 
N
N
Cl
R
4a H 1.1088 5.50 / 4.51522 4.47 ± 0.56 0.0 0.0 
4b 2-OCH3 1.1497 5.38 / 4.43422 4.47 ± 0.57 -0.390 [61] 6.5 
4c 3-OCH3 1.1827 5.38 / 4.43422 4.44 ± 0.57 0.115 6.5 
4d 4-OCH3 1.1337 5.38 / 4.43422 4.41 ± 0.57 -0.268 6.5 
4e 2,4-OCH3 1.1953 5.25 / 4.52322 4.30 ± 0.57 -0.658 13.0 
 
The presence of phenolic and carbonyl moieties decreased the lipophilicity. Nevertheless, the 
observation that the lipophilicity of compounds 3k and 3j was close to the lipophilicity of compound 2 
was unexpected. Compound 3f showed less lipophilicity compared with 3h. On the basis of 
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comparison of the lipophilicity data log k of both Br-substituted isomers 3g-3i, it can be stated that  
4-bromo derivative 3i possessed higher lipophilicity than the 3-bromo isomer 3h and the 2-bromo 
isomer 3g. A diverse trend can be observed at methoxy moiety substituted compounds 3b-e and 4b-e. 
Compounds 3e and 4e showed the highest lipophilicity, while compounds 3a and 4a possessed the 
lowest lipophilicity within individual series of methoxy moiety substituted compounds, according to 
log k data. Compounds 3a and 4a showed lower lipophilicity in comparison with the results calculated 
by the software. If the lipophilicity data log k of three position isomers 3b-d, 4b-d are compared, it 
can be stated that 3-methoxy derivative 3c/4c possessed higher lipophilicity than 2-methoxy derivative 
3b/4b and 4-methoxy derivative 3d/4d showed the lowest lipophilicity. 
Figure 1. Comparison of the log P/Clog P values computed using the two programs with 
the calculated log k values. The discussed compounds 1-4e are ordered according to the 
increase in log k values. 
-2.0
-1.0
0.0
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6.0
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Generally, based on the facts discussed above, it can be stated that intramolecular interactions, 
especially within styrylquinazolinone derivatives, play a significant role in the lipophilicity of the 
discussed compounds. It can be assumed that the determined log k data specify lipophilicity within the 
individual series of compounds. Lipophilicity increased in the following order: 2,3,4-OH < 4-CHO < 
H < 4-OCH3 < 2-OCH3 < 3-OCH3 < 2,4-OCH3 < 2-Br < 3-Cl < 3-Br < 4-Br. 
2.3. Inhibition of photosynthetic electron transport (PET) in spinach chloroplasts 
The evaluated quinazoline derivatives showed relatively low activity related to inhibition of 
photosynthetic electron transport (PET) in spinach chloroplasts (Table 2). Compounds 4a and 4c 
expressed the highest PET-inhibiting activity (IC50: 285 and 303 µmol/L, respectively). PET inhibition 
by several compounds (1, 3a-c, 3g, 3j and 4b) could not be determined due to precipitation of the 
compounds during the experiment and compound 3k interacted with the artificial electron acceptor 
DCPIP (change of the colour). The PET-inhibiting activity was expressed by negative logarithm of 
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IC50 value (compound concentration in mol/L causing 50% inhibition of PET). Despite the relatively 
low inhibitory activity of the studied compounds as well as the relative scarcity of compounds for 
which PET-inhibiting activity could be determined, the correlations between log (1/IC50) and log k or 
Hammett's parameters (σ) of the R substituent for both tested groups (3d-i, as well as 4a-d) were 
performed. The σ values [60,61] mentioned in Table 1 were used for calculations; the σ value for 
R: 2,4-OCH3 was calculated from the sum of corresponding σ values for R: 2-OCH3 and R: 4-OCH3. 
Table 2. IC50 values related to PET inhibition in spinach chloroplasts in comparison with 
3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU) standard and in vitro antimycobacterial 
activity MIC/IC90 of compounds 1-3i, 4a-4e in comparison with the standard, isoniazid 
(INH). 
Comp. 
PET inhibition 
IC50 [μmol/L] 
MIC/IC90 [µg/mL] 
M. smegmatis M. absessus M. kansasii M. avium complex 
1 a >300 >300 >300 >300 
2 362 >300 >300 >300 >300 
3a a >300 >300 >300 >300 
3b a >100 >100 >100 >100 
3c a >100 >100 >100 >100 
3d 693 >100 >100 >100 >100 
3e 391 >100 80 20 80 
3f 1034 >300 >300 >300 >300 
3g a >100 >100 >100 >100 
3h 561 >100 >100 >100 >100 
3i 665 >100 >100 >100 >100 
4a 285 >100 >100 >100 >100 
4b a >100 80 60 80 
4c 303 >100 >100 60 >100 
4d 390 >100 >100 >100 >100 
4e 508 >100 >100 >100 >100 
DCMU 1.9 – – – – 
INH – 39 >100 <10 <10 
a precipitation during the experiment or interaction with DCPIP. 
 
The importance of electronic properties of the R substituent was for the inhibitory activity (IC50 in 
mol/L) of compounds 3a-i unambiguously much more significant than the compound lipophilicity 
(log k): 
log (1/IC50) = 3.216 (± 0.048) – 0.218 (± 0.095) σ 
r = 0.798, s = 0.106, F = 5.26, n = 5     (1) 
log (1/IC50) = 3.545 (± 0.530) - 0.248 (± 0.374) log k 
r = 0.358, s = 0.160, F = 0.44, n = 5     (2) 
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Similarly, the inhibitory activity (IC50 in mol/L) of compounds 4a-e depended predominantly on 
the Hammett's constants (σ) of R substituents: 
log (1/IC50) = 3.507 (± 0.020) + 0.324 (± 0.056) σ 
r = 0.971, s = 0.033, F = 33.24, n = 4     (3) 
log (1/IC50) = 5.272 (± 1.900) – 1.584 (± 1.644) log k 
r = 0.563, s = 0.116, F = 0.93, n = 4     (4) 
From Equations 1-4 it is evident that in both studied groups of compounds (3d-i and 4a-d) the 
electronic properties of the R substituent were decisive for photosynthesis-inhibiting activity. For 
estimation of the potential contribution of the compound lipophilicity to its biological activity, a larger 
data set for both groups of compounds tested would be necessary. 
2.4. In vitro antimycobacterial evaluation 
Sixteen compounds 1-3i, 4a-4e were evaluated for their in vitro antimycobacterial activity against 
four mycobacterial strains and the results are shown in Table 2. According to the results, it is evident 
that the tested compounds were poorly soluble in the testing medium and therefore concentrations of 
the compounds in the medium were not sufficient for determination of real antimycobacterial activity. 
Due to this fact, it can be concluded that the majority of compounds evaluated did not show any 
significant antimycobacterial activity. Only 2-[(E)-2-(2,4-dimethoxyphenyl)vinyl]quinazolin-4(3H)-
one (3e) and 4-chloro-2-[(E)-2-(2-methoxyphenyl)vinyl]quinazoline (4b) expressed an interesting 
MIC especially against M. kansasii, M. avium complex and M. absessus. Both compounds were more 
active than INH in case of M. absessus. 
With the available data it is difficult to attempt to determine any structure-activity relationships, 
although some observations can be made. The 4-chloroquinazoline nucleus (series 4) seems to be 
more advantageous for higher antimycobacterial activity than the quinazolin-4(3H)-one scaffold 
(series 3); e.g., unsubstituted 3a showed lower activity than 4a. 
The benzylidene part of the molecule is also important for antimycobacterial activity. Bulk 
parameters (the volume of substituents) MR [60] are also very important for activity. According to 
Tables 1 and 2 it can be assumed that compounds with bulky substituents showed higher 
antimycobacterial activity. Unsubstituted compounds 3a and chloro substituted 3f possessed less 
activity than methoxy or bromo substituted compounds. The highest effect was shown by disubstituted 
2,4-methoxy derivative 3e. The position of substituents on the benzylidene part of the molecule is 
important especially for compounds within series 4; compare the activity of compounds 4b > 4c > 4d 
> 4e. 
2.5. In vitro antifungal susceptibility testing 
All quinazoline derivatives 1-4e were tested for their in vitro antifungal activity against eight fungal 
strains. The antifungal activity of all the compounds were in the range from >125 to >500 μmol/L and 
therefore the activities are not presented in detail. According to these results, it can be concluded that 
all the compounds are almost completely insoluble in aqueous solvents as they precipitated from the 
testing medium. Generally, compounds 1 and 2 showed lower activity than most compounds 3 and 4. 
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The substitution of benzylidene part of the molecule by 3-OCH3 (3c, 4c) or 2,3,4-OH (3k) seems to 
contribute to antifungal activity within both series of compounds. 
3. Conclusions 
Series of ring-substituted 2-styrylquinazolin-4(3H)-one and 4-chloro-2-styrylquinazoline 
derivatives were prepared and characterized. All eighteen prepared quinazoline derivatives were 
analyzed using a RP-HPLC method for lipophilicity measurement and their lipophilicity was 
determined. The prepared compounds were tested for their antifungal and antimycobacterial activity 
and for their activity related to the inhibition of photosynthetic electron transport (PET) in spinach 
chloroplasts (Spinacia oleracea L.). 2-[(E)-2-(2,4-Dimethoxyphenyl)vinyl]quinazolin-4(3H)-one (3e) 
and 4-chloro-2-[(E)-2-(2-methoxyphenyl)vinyl]quinazoline (4b) exhibited the highest in vitro 
antimycobacterial activity. 4-Chloro-2-[(E)-2-(3-methoxyphenyl)vinyl]quinazoline (4c) showed the 
highest PET-inhibiting activity. 
4. Experimental 
4.1. General 
All reagents were purchased from Aldrich. Kieselgel 60, 0.040–0.063 mm (Merck, Darmstadt, 
Germany) was used for column chromatography. TLC experiments were performed on alumina-
backed silica gel 40 F254 plates (Merck, Darmstadt, Germany). The plates were illuminated under UV 
(254 nm) and evaluated in iodine vapour. The melting points were determined on Boetius PHMK 05 
(VEB Kombinat Nagema, Radebeul, Germany) and are uncorrected. The purity of the final 
compounds was checked by the HPLC separation module Waters Alliance 2695 XE (Waters Corp., 
Milford, MA, U.S.A.). The detection wavelength 210 nm was chosen. The peaks in the chromatogram 
of the solvent (blank) were deducted from the peaks in the chromatogram of the sample solution. The 
purity of individual compounds was determined from the area peaks in the chromatogram of the 
sample solution. UV spectra (λ, nm) were determined on a Waters Photodiode Array Detector 2996 
(Waters Corp., Milford, MA, U.S.A.) in ca 6×10-4 mol methanolic solution and log ε (the logarithm of 
molar absorption coefficient ε) was calculated for the absolute maximum λmax of individual target 
compounds. Infrared spectra were recorded using KBr pellets on the FT-IR spectrometer Nicolet 6700 
(Nicolet - Thermo Scientific, U.S.A.). All 1H-NMR spectra were recorded on a Bruker AM-500 
(499.95 MHz for 1H) instrument (Bruker BioSpin Corp., Germany). Chemicals shifts are reported in 
ppm (δ) to internal Si(CH3)4, when diffused easily exchangeable signals are omitted. 
4.2. Synthesis 
2-Methylquinazolin-4(3H)-one (1): Yield 77% of a white crystalline compound; mp 245-247 °C (lit. 
mp 242-244 °C [62]); HPLC purity: 98.64%; UV (nm), λmax/log ε: 305.1/3.53; 1H-NMR [(CD3)2CO] 
δ: 2.45 (s, 3H, CH3), 7.44 (t, 1H, Ar-H), 7.59 (d, J = 8.15 Hz, 1H, Ar-H), 7.76 (t, 1H, Ar-H), 8.13 (d,  
J = 7.94 Hz, 1H, Ar-H), 11.00 (s, 1H, NH). 
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3-(2-Hydroxyethyl)-2-methylquinazolin-4(3H)-one (2). Yield 52% of a white crystalline compound; 
mp 154-156 °C; HPLC purity: 99.67%; UV (nm), λmax/log ε: 305.8/3.58; 1H-NMR (DMSO-d6) δ: 2.65 
(s, 3H, CH3), 3.66 (q, 2H, CH2), 4.12 (t, 2H, CH2), 5.00 (t, 1H, OH), 7.46 (t, 1H, Ar-H), 7.57  
(d, J = 8.14 Hz, 1H, Ar-H), 7.77 (t, 1H, Ar-H), 8.08 (d, J = 8.00 Hz, 1H, Ar-H). 
4.2.1. General procedures of synthesis of Compounds 3a-k 
A mixture of compound 1 (0.01 mol) and the appropriate aldehyde (0.02 mol) was mixed 
thoroughly and irradiated in monomode cavity of microwave reactor using pulse sequence  
(3×5 minutes with 30 sec. intervals) at 250 W. During irradiation, the temperature was controlled 
between the range 150-180 °C. After the reaction, the mixture was cooled and washed with boiling 
ether. The product was crystallized from acetic acid. 
 
2-(E)-Styrylquinazolin-4(3H)-one (3a). [63] Yield 50% of a white crystalline compound;  
mp 253-255 °C (lit. mp 252 °C [64]); HPLC purity: 97.95%; UV (nm), λmax/log ε: 321.3/3.53;  
1H-NMR (DMSO-d6) δ: 7.00 (d, J = 16.23 Hz, 1H, C=C-H), 7.41 (t, 1H, Ar-H), 7.42-7.49 (m, 3H,  
Ar-H), 7.65-7.68 (m, 3H, Ar-H), 7.80 (t, 1H, Ar-H), 7.95 (d, J = 16.16 Hz, 1H, C=C-H), 8.10 (d, 1H, 
Ar-H), 12.35 (s, 1H, N-H). 
 
2-[(E)-2-(2-Methoxyphenyl)vinyl]quinazolin-4(3H)-one (3b). [63] Yield 76% of a white crystalline 
compound; mp 234-236 °C (lit. mp 234-236 °C [64]); HPLC purity: 94.04%; UV (nm), λmax/log ε: 
343.4/3.62; 1H-NMR (DMSO-d6) δ: 3.90 (s, 3H, OCH3), 7.02 (t, 1H, Ar-H), 7.07 (d, J = 16.24 Hz, 1H, 
C=C-H), 7.11 (d, 1H, Ar-H), 7.39 (t, 1H, Ar-H), 7.45 (t, 1H, Ar-H), 7.60 (d, 1H,  
Ar-H), 7.67 (d, 1H, Ar-H), 7.79 (t, 1H, Ar-H), 8.09 (d, 1H, Ar-H), 8.15 (d, J = 16.12 Hz, 1H, C=C-H), 
12.36 (s, 1H, N-H). 
 
2-[(E)-2-(3-Methoxyphenyl)vinyl]quinazolin-4(3H)-one (3c). [63] Yield 68% of a white crystalline 
compound; mp 239-241 °C; HPLC purity: 96.82%; UV (nm), λmax/log ε: 326.4/3.58; 1H-NMR 
(DMSO-d6) δ: 3.81 (s, 3H, OCH3), 6.98 (d, 1H, Ar-H), 7.01 (d, J = 16.81 Hz, 1H, C=C-H), 7.22 (s, 
1H, Ar-H), 7.23 (d, 1H, Ar-H), 7.37 (t, 1H, Ar-H), 7.47 (t, 1H, Ar-H), 7.66 (d, 1H, Ar-H), 7.80 (t, 1H,  
Ar-H), 7.91 (d, J = 16.14 Hz, 1H, C=C-H), 8.10 (d, 1H, Ar-H), 12.31 (s, 1H, NH). 
 
2-[(E)-2-(4-Methoxyphenyl)vinyl]quinazolin-4(3H)-one (3d). [63] Yield 33% of a white crystalline 
compound; mp 280-281 °C (lit. mp 284-285 °C [64]); HPLC purity: 94.36%; UV (nm), λmax/log ε: 
322.7/3.59; 1H-NMR (DMSO-d6) δ: 3.80 (s, 3H, OCH3), 6.84 (d, J = 16.23 Hz, 1H, C=C-H), 7.01 (d, 
2H, Ar-H), 7.45 (t, 1H, Ar-H), 7.60 (d, 2H, Ar-H), 7.64 (d, 1H, Ar-H), 7.78 (t, 1H, Ar-H), 7.90  
(d, J = 16.08 Hz, 1H, C=C-H), 8.08 (d, 1H, Ar-H), 12.25 (s, 1H, N-H). 
 
2-[(E)-2-(2,4-Dimethoxyphenyl)vinyl]quinazolin-4(3H)-one (3e). [63] Yield 57% of a white 
crystalline compound; mp 228-230 °C (lit. mp 228-230 °C [64]); HPLC purity: 96.27%; UV (nm), 
λmax/log ε: 350.1/3.67; 1H-NMR (DMSO-d6) δ: 3.82 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 6.63 (d, 1H, 
Ar-H), 6.64 (s, 1H, Ar-H), 6.94 (d, J = 16.15 Hz, 1H, C=C-H), 7.43 (t, 1H, Ar-H), 7.53 (d, 1H, Ar-H), 
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7.64 (d, 1H, Ar-H), 7.77 (t, 1H, Ar-H), 8.07 (d, J = 15.21 Hz, 1H, C=C-H), 8.08 (d, 1H, Ar-H), 12.26 
(s, 1H, N-H). 
 
2-[(E)-2-(3-Chlorophenyl)vinyl]quinazolin-4(3H)-one (3f). [63] Yield 93% of a white crystalline 
compound; mp 289 °C; HPLC purity: 96.51%; UV (nm), λmax/log ε: 326.4/3.59; 1H-NMR (CDCl3) δ: 
6.93 (d, J = 16.41 Hz, 1H, C=C-H), 7.39 (d, 2H, Ar-H), 7.46-7.53 (m, 2H, Ar-H), 7.64 (s, 1H, Ar-H), 
7.79 (d, J = 16 Hz, 1H, C=C-H), 7.77-7.83 (m, 2H, Ar-H), 8.33 (d, 1H, Ar-H), 10.64 (s, 1H, NH). 
 
2-[(E)-2-(2-Bromophenyl)vinyl]quinazolin-4(3H)-one (3g). [63] Yield 71% of a white crystalline 
compound; mp 279 °C; HPLC purity: 98.84%; UV (nm), λmax/log ε: 326.9/3.59; 1H-NMR (CDCl3) δ: 
6.93 (d, J = 16.47 Hz, 1H, C=C-H), 7.40 (t, 1H, Ar-H), 7.50 (t, 1H, Ar-H), 7.67 (d,  
J = 7.90 Hz, 1H, Ar-H), 7.74-7.82 (m, 4H, Ar-H), 8.12 (d, J = 16.45 Hz, 1H, C=C-H), 8.36 (d,  
J = 7.88 Hz, 1H, Ar-H), 10.96 (s, 1H, NH). 
 
2-[(E)-2-(3-Bromophenyl)vinyl]quinazolin-4(3H)-one (3h). [63] Yield 43% of a white crystalline 
compound; mp 277-279 °C; HPLC purity: 97.34%; UV (nm), λmax/log ε: 326.4/3.58; 1H-NMR 
(CDCl3) δ: 6.91 (d, J = 16.33 Hz, 1H, C=C-H), 7.33 (t, 1H, Ar-H), 7.50-7.56 (m, 2H, Ar-H), 7.55 (s, 
1H, Ar-H), 7.73 (d, J = 16.49 Hz, 1H, C=C-H), 7.76-7.82 (m, 3H, Ar-H), 8.33 (d, 1H, Ar-H), 10.31 (s, 
1H, NH). 
 
2-[(E)-2-(4-Bromophenyl)vinyl]quinazolin-4(3H)-one (3i). [63] Yield 66% of a white crystalline 
compound; mp 332 °C; HPLC purity: 97.64%; UV (nm), λmax/log ε: 326.7/3.58; 1H-NMR (DMSO-d6) 
δ: 7.03 (d, 1H, C=C-H), 7.49 (t, 1H, Ar-H), 7.61 (d, 1H, Ar-H), 7.64 (d, 2H, Ar-H), 7.66 (d, 1H,  
Ar-H), 7.68 (d, 1H, Ar-H), 7.81 (t, 1H, Ar-H), 7.91 (d, 1H, C=C-H), 8.11 (d, 1H, Ar-H), 12.36 (s, 1H, 
N-H). 
 
2-[(E)-2-(4-Carbaldehydephenyl)vinyl]quinazolin-4(3H)-one (3j). [63] Yield 35% of a white 
crystalline compound; mp 218 °C; HPLC purity: 96.93%;. UV (nm), λmax/log ε: 337.9/3.69; 1H-NMR 
(CDCl3) δ: 7.16 (d, J = 16.13 Hz, 1H, C=C-H), 7.50 (t, 1H, Ar-H), 7.69 (d, 2H, Ar-H), 7.82 (t, 1H,  
Ar-H), 7.87 (d, 1H, Ar-H), 7.97 (d, 1H, Ar-H), 8.00 (d, J = 16.21 Hz, 1H, C=C-H), 8.11 (d, 2H, Ar-H), 
9.95 (s, 1H, CHO), 10.02 (s, 1H, N-H). 
 
2-[(E)-2-(2,3,4-Trihydroxyphenyl)vinyl]quinazolin-4(3H)-one (3k). [63] Yield 60% of a brown 
crystalline compound; mp 300 °C (decomp.); HPLC purity: 97.67%; UV (nm), λmax/log ε: 365.0/3.65; 
1H-NMR (DMSO-d6), δ: 6.39 (d, 1H, Ar-H), 6.83 (d, J = 15.98 Hz, 1H, C=C-H), 6.88 (d, 1H, Ar-H), 
7.40 (t, 1H, Ar-H), 7.63 (d, 1H, Ar-H), 7.75 (t, 1H, Ar-H), 8.05 (d, 1H, Ar-H), 8.10 (d, J = 16.05 Hz, 
1H, C=C-H), 8.57 (s, 1H, OH), 9.07 (s, 1H, OH), 9.68 (s, 1H, OH), 12.19 (s, 1H, NH). 
4.2.2. General procedures of synthesis of Compounds 4a-e 
A mixture of styrylquinazolinone derivatives 3 (0.01 mol), N,N-dimethylaniline (0.02 mol) and 
phosphorus oxychloride (0.015 mol) in dry benzene (50 mL) was stirred and heated under reflux for  
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3 h. The reaction mixture was then cooled and filtered. The filtrate was diluted with benzene (30 mL) 
and the solution washed with water (50 mL), twice with 20 % aqueous NaOH (50 mL) and finally 
twice with water. After drying with MgSO4, the organic solvent was evaporated and the product 
obtained was crystallized from heptane. 
 
4-Chloro-2-(E)-styrylquinazoline (4a). [63] Yield 81% of an orange crystalline compound; mp 
104 °C, (lit. mp 100-101 °C [65]); HPLC purity: 99.34%; UV (nm), λmax/log ε: 314.9/3.67; 1H-NMR  
(DMSO-d6) δ: 7.34 (d, J = 15.91 Hz, 1H, C=C-H), 7.41 (t, 1H, Ar-H), 7.47 (t, 2H, Ar-H), 7.77-7.80 
(m, 3H, Ar-H), 8.02 (d, 1H, Ar-H), 8.06 (t, 1H, Ar-H), 8.12 (d, J = 16.01 Hz, 1H, C=C-H), 8.26 (d, 
1H,Ar-H). 
 
4-Chloro-2-[(E)-2-(2-methoxyphenyl)vinyl]quinazoline (4b). [63] Yield 86% of a light yellow 
crystalline compound; mp 153 °C; HPLC purity: 99.95%; UV (nm), λmax/log ε: 345.1/3.67; 1H-NMR 
(DMSO-d6) δ: 3.98 (s, 3H, OCH3), 7.04 (t, 1H, Ar-H), 7.12 (d, 1H, Ar-H), 7.37 (d, J = 16.15 Hz, 1H, 
C=C-H), 7.40 (t, 1H, Ar-H), 7.78 (t, 1H, Ar-H), 7.82 (d, 1H, Ar-H), 8.01 (d, 1H, Ar-H), 8.06 (t, 1H, 
Ar-H), 8.27 (d, 1H, Ar-H), 8.47 (d, J = 16.15 Hz, 1H, C=C-H). 
 
4-Chloro-2-[(E)-2-(3-methoxyphenyl)vinyl]quinazoline (4c). [63] Yield 81% of a light yellow 
crystalline compound; mp 137 °C; HPLC purity: 98.62%; UV (nm), λmax/log ε: 342.9/3.64; 1H-NMR 
(DMSO-d6) δ: 3.90 (s, 3H, OCH3), 6.98 (d, 1H, Ar-H), 7.35 (d, J = 15.75 Hz, 1H, C=C-H), 7.35-7.39 
(m, 2H, Ar-H), 7.36 (s, 1H, Ar-H), 7.80 (t, 1H, Ar-H), 8.02 (d, 1H, Ar-H), 8.06 (d, 1H, Ar-H), 8.10 (d, 
J = 15.82 Hz, 1H, C=C-H), 8.28 (d, 1H, Ar-H). 
 
4-Chloro-2-[(E)-2-(4-methoxyphenyl)vinyl]quinazoline (4d). [63] Yield 51% of a yellow crystalline 
compound; mp 130-131 °C, (lit. mp 130-131 °C [65]); HPLC purity: 97.43%; UV (nm), λmax/log ε: 
339.9/3.64; 1H-NMR (DMSO-d6) δ: 3.87 (s, 3H, OCH3), 7.03 (d, 2H, Ar-H), 7.20 (d, J = 15.87 Hz, 
1H, C=C-H), 7.75 (d, 2H, Ar-H), 7.76 (t, 1H, Ar-H), 7.99 (d, 1H, Ar-H), 8.04 (t, 1H, Ar-H), 8.08  
(d, J = 15.89 Hz, 1H, C=C-H), 8.25 (d, 1H, Ar-H). 
 
4-Chloro-2-[(E)-2-(2,4-dimethoxyphenyl)vinyl]quinazoline (4e). [63] Yield 48% of a yellow 
crystalline compound; mp 172 °C; HPLC purity: 98.57%; UV (nm), λmax/log ε: 355.0/3.67;  
IR (KBr, cm-1): 2980, 2938, 1607, 1556, 1504, 1477, 1450, 1384, 1329, 959, 768, 756; 1H-NMR 
[(CD3)2CO] δ: 3.88 (s, 3H, OCH3), 3.98 (s, 3H, OCH3), 6.64 (d, 1H, Ar-H), 6.66 (s, 1H, Ar-H), 7.27 
(d, J=16.13 Hz, 1H, C=C-H), 7.75 (d, 1H, Ar-H), 7.60 (t, 1H, Ar-H), 7.98 (d, 1H, Ar-H), 8.02 (t, 1H, 
Ar-H), 8.25 (d, 1H, Ar-H), 8.40 (d, J=16.13 Hz, 1H, C=C-H). 
4.3. Lipophilicity HPLC determination (capacity factor k / calculated log k) 
The HPLC separation module Waters Alliance 2695 XE and Waters Photodiode Array Detector 
2996 (Waters Corp., Milford, MA, U.S.A.) were used. The chromatographic column Symmetry® C18  
5 μm, 4.6 × 250 mm, Part No. WAT054275, (Waters Corp., Milford, MA, U.S.A.) was used. The 
HPLC separation process was monitored by Millennium32® Chromatography Manager Software, 
Molecules 2009, 14                            
 
 
4259
Waters 2004 (Waters Corp.). The mixture of MeOH p.a. (55.0%) and H2O-HPLC – Mili-Q Grade 
(45.0%) was used as a mobile phase. The total flow of the column was 0.9 mL/min, injection 30 μL, 
column temperature 30 °C and sample temperature 10 °C. The detection wavelength 210 nm was 
chosen. The KI methanolic solution was used for the dead time (tD) determination. Retention times (tR) 
were measured in minutes. The capacity factors k were calculated using the Millennium32® 
Chromatography Manager Software according to formula k = (tR - tD)/tD, where tR is the retention time 
of the solute, whereas tD denotes the dead time obtained via an unretained analyte. The log k values, 
calculated from the capacity factor k of the individual compounds, are shown in Table 1. 
4.4. Lipophilicity calculations 
Log P, i.e., the logarithm of the partition coefficient for n-octanol/water, was calculated using the 
programs CS ChemOffice Ultra ver. 10.0 (CambridgeSoft, Cambridge, MA, U.S.A.) and ACD/LogP 
ver. 1.0 (Advanced Chemistry Development Inc., Toronto, Canada). Clog P values (the logarithm of  
n-octanol/water partition coefficient based on established chemical interactions) were generated by 
means of the CS ChemOffice Ultra ver. 10.0 software. The results are shown in Table 1. 
4.5. Study of inhibition photosynthetic electron transport (PET) in spinach chloroplasts 
Chloroplasts were prepared from spinach (Spinacia oleracea L.) according to Masarovicova and 
Kralova [66]. The inhibition of photosynthetic electron transport (PET) in spinach chloroplasts was 
determined spectrophotometrically (Genesys 6, Thermo Scientific, U.S.A.) using an artificial electron 
acceptor 2,6-dichlorophenol-indophenol (DCIPP) according to Kralova et al. [67] and the rate of 
photosynthetic electron transport was monitored as a photoreduction of DCPIP. The measurements 
were carried out in phosphate buffer (0.02 mol/L, pH 7.2) containing sucrose (0.4 mol/L), MgCl2 
(0.005 mol/L) and NaCl (0.015 mol/L). The chlorophyll content was 30 mg/L in these experiments 
and the samples were irradiated (~100 W/m2) from 10 cm distance with a halogen lamp (250 W) using 
a 4 cm water filter to prevent warming of the samples (suspension temperature 22 °C). The studied 
compounds were dissolved in DMSO due to their limited water solubility. The applied DMSO 
concentration (up to 4%) did not affect the photochemical activity in spinach chloroplasts. The 
inhibitory efficiency of the studied compounds was expressed by IC50 values, i.e. by molar 
concentration of the compounds causing 50% decrease in the oxygen evolution rate relative to the 
untreated control. The comparable IC50 value for a selective herbicide 3-(3,4-dichlorophenyl)-1,1-
dimethylurea, DCMU (Diuron®) was about 1.9 μmol/L [68]. The results are summarized in Table 2. 
4.6. In vitro antimycobacterial evaluation 
Clinical isolates of Mycobacterium avium complex CIT19/06, M. kansasii CIT11/06, M. absessus 
CIT21/06 and strain M. smegmatis MC2155 were grown in Middlebrook broth (MB), supplemented 
with OADC supplement (Oleic, Albumin, Dextrose, Catalase, Becton Dickinson, U.K.). Identification 
of these isolates was performed using biochemical and molecular protocols. At log phase growth, the 
10 mL culture was centrifuged at 15,000 RPM for 20 minutes using a bench top centrifuge (Model CR 
4-12 Jouan Inc. U.K). Following the removal of the supernatant, the pellet was washed in fresh 
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Middlebrook 7H9GC broth and re-suspended in 10 mL of fresh supplemented MB. The turbidity was 
adjusted to match McFarland standard No. 1 (3 × 108 CFU) with MB broth. A further 1:20 dilution of 
the culture was then performed in MB broth. 
The antimicrobial susceptibility of all four mycobacteria was investigated in 96 well plate format. 
Here, sterile deionised water (150 µL) was added to all outer-perimeter wells of the plates to minimize 
evaporation of the medium in the test wells during incubation. Each dilution (150 µL) was incubated 
with each of the mycobacterial species (150 µL). Dilutions of each compound were prepared in 
duplicate. For all synthesized compounds, final concentrations ranged from 300 µg/mL to 10 µg/mL. 
All compounds were prepared in DMSO and subsequent dilutions were made in supplemented 
Middlebrook broth. The plates were sealed with parafilm and were incubated at 37 °C overnight in the 
case of M. smegmatis and M. absessus and for five days in the case of M. kansasii and M. avium 
complex. Following incubation, a 10% addition of alamarBlue (AbD Serotec) was mixed into each 
well and readings at 570 nm and 600 nm were taken, initially for background subtraction and 
subsequently after 24 hour re-incubation. The background subtraction is necessary with strongly 
coloured compounds which may interfere with the interpretation of any colour change. In  
non-interfering compounds, a blue colour in the well was interpreted as an absence of growth, and  
a pink colour was scored as growth. The MIC was initially defined as the lowest concentration which 
prevented a visual colour change from blue to pink. The results are shown in Table 2. 
4.7. In vitro antifungal susceptibility testing 
The broth microdilution test [69,70] was used for the assessment of in vitro antifungal activity of 
the synthesized compounds against Candida albicans ATCC 44859 (CA), Candida tropicalis 156 
(CT), Candida krusei ATCC 6258 (CK), Candida glabrata 20/I (CG), Trichosporon asahii 1188 
(TA), Aspergillus fumigatus 231 (AF), Absidia corymbifera 272 (AC), and Trichophyton 
mentagrophytes 445 (TM). Fluconazole (FLU) was used as the standard of a clinically used 
antimycotic drug. The procedure was performed with twofold dilution of the compounds in RPMI 
1640 (Sevapharma a.s., Prague, Czech Republic) buffered to pH 7.0 with 0.165 mol of 3-morpholino-
propane-1-sulfonic acid (MOPS, Sigma, Germany). The final concentrations of the compounds ranged 
from 500 to 0.975 μmol/L. Drug–free controls were included. The MIC was defined as an 80% or 
greater (IC80) reduction of growth in comparison with the control. The values of MICs were 
determined after 24 and 48 h of static incubation at 35 °C. For T. mentagrophytes, the final MICs were 
determined after 72 and 120 h of incubation. The results are summarized in Table 3. 
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